Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Ferring Pharmaceuticals

    - PMLiVE

    Pfizer’s PADCEV gets FDA approval for bladder cancer

    Bladder cancer affects more than 614,000 people globally each year

    - PMLiVE

    Lilly and MeiraGTx partner in $475m ophthalmology deal

    The companies will develop and commercialise therapies for genetic conditions

    - PMLiVE

    Merck and Blackstone agree on funding for cancer protein antibody

    The funding will support late-stage clinical development of the investigational antibody-drug conjugate

    - PMLiVE

    Johnson & Johnson’s TAR-200 granted FDA priority review to treat bladder cancer

    An estimated 84,870 people will be diagnosed with bladder cancer in the US this year

    - PMLiVE

    AstraZeneca’s Imfinzi regimen approved by EC to treat muscle-invasive bladder cancer

    More than 35,000 people in five major European countries were treated for the disease last year

    - PMLiVE

    AstraZeneca receives CHMP recommendation for Imfinzi regimen in bladder cancer

    More than 614,000 cases of bladder cancer are diagnosed globally every year

    - PMLiVE

    Johnson & Johnson’s bladder cancer therapy Balversa accepted by SMC

    Almost 1,700 people are diagnosed with bladder cancer in Scotland annually

    - PMLiVE

    AstraZeneca announces positive phase 3 results for Imfinzi in high-risk bladder cancer

    Around half of NMIBC patients are classed as being high-risk for disease progression or recurrence

    The (clinical) trials and tribulations of gene therapy – why meaningful patient engagement strategies matter

    By Sarah Mohamad and Lauren Coleman-Bennett

    Amiculum

    - PMLiVE

    Pfizer’s sasanlimab improves event-free survival in phase 3 bladder cancer trial

    As many as half of patients with high-risk NMIBC experience disease recurrence despite BCG treatment

    What do people look for in gene therapy materials? Results from our survey of patients and relatives

    By Sam Fraser

    Amiculum

    - PMLiVE

    AstraZeneca’s Imfinzi regimen approved by FDA to treat bladder cancer

    Around half of patients who undergo bladder removal surgery experience disease recurrence

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links